非清髓性造血干细胞移植对比持续疾病修饰治疗对复发缓解型多发性硬化疾病进展的影响:一项随机临床试验
该随机临床试验纳入110例复发缓解型多发性硬化患者,比较非清髓性造血干细胞移植与疾病修饰治疗对疾病进展的影响。无死亡及非造血系统4级毒性发生。
要点
- 非清髓性HSCT较DMT显著延长疾病进展时间(HR 0.07)。
- 未观察到死亡或非造血系统4级毒性。
核心结论
- 在复发缓解型MS患者中,与DMT相比,非清髓性HSCT延长了疾病进展时间。
- 需进一步研究重复这些发现并评估长期结局与安全性。
研究设计与样本
- 随机临床试验,2005年9月20日至2016年7月7日在美国、欧洲和南美洲4个中心进行。
- 纳入110例复发缓解型MS患者,随机分配至HSCT组(n=55)或DMT组(n=55)。
- HSCT方案为环磷酰胺200 mg/kg联合抗胸腺细胞球蛋白6 mg/kg。
- DMT为高效或与既往不同类别的疾病修饰治疗。
- 主要终点为疾病进展,定义为至少1年后EDSS评分增加≥1.0分,且间隔6个月的两次评估确认。
主要发现
- HSCT组3例发生疾病进展,DMT组34例发生疾病进展。
- DMT组中位进展时间为24个月(IQR 18-48),HSCT组因事件太少无法计算。
- 无死亡,HSCT组无非造血系统4级毒性。
关键数值与推荐
- 纳入标准:复发缓解型MS,既往一年接受DMT期间至少2次复发,EDSS评分2.0-6.0。
- 疾病进展定义:EDSS增加≥1.0分(最小临床重要差异0.5),间隔6个月两次评估确认。
- 主要终点采用风险比估计时间至进展差异。
临床怎么用
- 对于既往DMT治疗下仍频繁复发的复发缓解型MS患者,非清髓性HSCT可能延缓疾病进展。
- 需权衡HSCT的潜在风险与DMT的持续治疗需求。
- 该研究为初步结果,需进一步验证长期疗效与安全性。
局限性
- 中位随访仅2年,长期结局未知。
- 样本量较小(110例),需更大规模研究重复。
- HSCT组事件数少,中位进展时间无法计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). OBJECTIVE: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. DESIGN, SETTING, AND PARTICIPANTS: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018. INTERVENTIONS: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55). MAIN OUTCOMES AND MEASURES: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. RESULTS: Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P < .001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95% CI, -2.03 to -1.29; P < .001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events). CONCLUSIONS AND RELEVANCE: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00273364.
引用
- Burt RK, Balabanov R, Burman J, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019. PMID: 30644983. doi:10.1001/jama.2018.18743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。